OBR Daily Commentary

forumImage

AstraZeneca Reports Results From the ARCTIC Trial In Third-Line Non-Small Cell Lung Cancer

(AstraZeneca) Apr 24, 2018 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments.

Read Article arrow

H. Jack West, MD (Posted: April 24, 2018)

quotesThis is a disappointing result, particularly considering how low the bar is to beat third line standard of care in advanced NSCLC, and in the context of so many positive trials of immunotherapy in other lung cancer settings. Moreover, this report should only further lower our expectations for the MYSTIC trial with this combination in first line NSCLC (if that's possible at this point) and I think causes some collateral damage to nivo/ipi as another PD-L1/CTLA-4 inhibitor combination that is "on the bubble" in terms of how to interpret the data thus far. Perhaps the results would look convincingly more favorable if AZ were to focus on a molecularly defined subset, as BMS morphed the recent CheckMate 227 AACR presentation and publication into a focus on patients with high tumor mutation burden. Regardless, this is unwelcome news for a checkpoint inhibitor strategy several steps behind others in NSCLC.quotes

Add Comment 1 Comment
forumImage

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review

(BMS) Apr 18, 2018 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with small cell lung cancer (SCLC) whose disease has progressed after two or more prior lines of therapy. The FDA action date is August 16, 2018.

Read Article arrow

H. Jack West, MD (Posted: April 19, 2018)

quotesThis will be a welcome addition to our very limited armamentarium for small cell lung cancer. This is a setting in which topotecan is approved, but I don't think there's another approved agent in oncology less enthusiastically endorsed in practice. It's activity is very marginal, toxicity is significant, particularly if administered as it was actually approved, at a dose that is extremely prone to prohibitive myelosuppression. Based on these issues, those who treat relapsed small cell lung cancer have eagerly awaited ANY viable alternative. Though only a minority of patients respond well to nivolumab, the same can be said for topotecan, but nivolumab is typically associated with far more manageable and modest toxicities, and there is a real chance for a more sustained benefit than we could ever anticipate with more conventional chemotherapy. Notably, nivolumab is already listed as a leading consideration in the NCCN guidelines, but it would be very welcome to have a formal FDA approval for nivolumab in this setting. We can also look forward to far more clinical data on nivolumab +/- ipilimumab in SCLC in the coming years.quotes

Add Comment 1 Comment
forumImage

US FDA Approves Tagrisso As 1st-Line Treatment For EGFR-mutated Non-small Cell Lung Cancer

(AstraZeneca) Apr 18, 2018 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.

Read Article arrow

H. Jack West, MD (Posted: April 19, 2018)

quotesA long overdue approval that most lung cancer specialists should have come shortly after presentation of the FLAURA trial comparing first line osimertinib to "standard of care" first generation EGFR TKI (either gefitinib or erlotinib) in systemic therapy-naive EGFR mutation-positive NSCLC. The PFS benefit was very substantial (median 18.9 vs. 10.2 mo, HR below 0.5), and osimertinib also has much greater CNS activity to control the risk of future brain mets (quite common in EGFR mutation-positive NSCLC) and also has a more favorable toxicity profile. Though some oncologists and patients will invariably want to hold out on osimertinib and "save" it as a second line therapy to preserve a backup option, that's an erroneous approach, I would content. If it's reserved for later, a maximum of only 50-60% of patients who develop T790M-positive acquired resistance will qualify for it, and only a limited subset of those patients will actually undergo testing to find it. If osimertinib is used as first line therapy, 100% of eligible patients will receive the benefits from it. If it is reserved for second line, likely well under 50% and more like 30-40% of initially eligible patients will ultimately receive it. Overall, the population will likely to far better by starting with osimertinib.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...